This project aims to investigate the protective mechanism of low-dose Lipopolysaccharide (LPS) on RAW264.7 macrophages treated with antitumor drugs, specifically Adriamycin. We utilized LC-MS/MS based quantitative proteomics to identify differentially expressed proteins. The results provide insights into how LPS induces drug efflux and enhances macrophage survival through the regulation of drug resistance-associated proteins.